

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

# Characterisation RyR1 variants linked to malignant hyperthermia

A thesis presented to Massey University in partial fulfilment of the requirements for a  
Masters of Science in Biochemistry.

Jeremy Stephens

2016

## Acknowledgements

Firstly, and most formally, I would like to thank my supervisor Professor Kathryn Stowell for giving me the opportunity to work in your lab. Thank you for all the help and support you have been kind enough to provide over the past two years.

Secondly, I would like to thank my co supervisor Associate Professor Andrew Sutherland-Smith. Thank you for always making time to provide help and advice during this project.

I would like to thank the current and past members of the Twilite zone. Anja, thank you for all the time you have spent trouble shooting and providing advice. Lili, thank you for all the help you were kind enough to provide. Remai, thank you for all of your support and always being happy to help out with any problems I had. Sean, thanks for the support. Ruth, thanks for the support and encouragement. Bex, while you were not directly involved with my work thank you for helping out when possible.

I would like to thank Associate Professor Gill Noris and Dr Mark Patchett. Thank you for always making time to provide help and advice along with providing some reagents that may have not been directly available to myself.

Trevor Loo, thank you for always making time to provide help throughout the past two years. The expression of the ryanodine receptor will have been very difficult without your help. Thank you for performing mass spectrometry.

Thank you Niki Murray for your help performing microscopy.

## Abstract

Malignant hyperthermia is a potentially fatal disorder of skeletal muscle manifesting as a rise in body temperature in response to inhalational anaesthetics and muscle relaxants. Further clinical signs include muscle rigidity and increased oxygen consumption. The increased metabolism is induced by alterations to  $\text{Ca}^{2+}$  homeostasis resulting from the dysregulation of the sarcoplasmic reticulum protein the ryanodine receptor type 1 (RyR1). A large proportion of known malignant hyperthermia linked genetic variants reside within the gene encoding the type 1 ryanodine receptor, *RYR1*. Malignant hyperthermia can be diagnosed by *in vitro* contracture testing of biopsied muscle tissue. The use of DNA diagnostic testing is advantageous, however it is limited to only 35 of the proposed 400 *RYR1* linked variants known to be associated with malignant hyperthermia.

The research described in this thesis reports the functional characterisation of two *RYR1* variants linked to malignant hyperthermia, c.641C>T and c.7042\_7044delCAG resulting in the amino acid changes p.T214M and p.ΔE2348. The ability of each variant to release  $\text{Ca}^{2+}$  in response to a stimulus was examined in a heterologous system. The variant p.ΔE2348 was shown to be hyperactive in response to agonists indicating the variant is the cause of malignant hyperthermia, while the p.T214M variant does not appear to have an effect on ryanodine receptor function.

To understand the relationship between RyR1 function and any structural alterations induced by the p.T214M and p.ΔE2348 variants, the domain housing each variant was cloned for bacterial expression. Subsequent purification and structural characterisation could be used to explain the role each variant plays with respect to the onset of MH. The RyR1 N-terminal domain, amino acids 1-558, and helical domain, amino acids 2091-2525, were expressed in *E. coli* and partially purified. The domains were shown to be soluble and stable following expression.

## Abbreviations

A280	Absorbance at 280 nm
ABC	Ammonium bicarbonate
ACN	Acetonitrile
AM	Acetoxymethyl
ADP	Adenosine di-phosphate
ATP	Adenosine tri-phosphate
Bp	Base pairs
Casq	Calsequestrin
CCD	Central core disease
cDNA	Complementary DNA
DAPI	4',6'-diamidino-2-phenylindole
DHPR	Dihydropyridine receptor
DMEM	Dulbecco's modified eagle's medium
DMSO	Dimethyl sulphoxide
DNA	Deoxyribonucleic acid
DP4	Domain peptide 4
DTT	Dithiothreitol
Dyspedic	Lack of the ryanodine receptor type 1 gene
<i>E. coli</i>	<i>Escherichia coli</i>
EC	Excitation-contraction
EC <sub>50</sub>	Half maximal effective concentration
EDTA	Ethlenediaminetetraacetic acid
EGTA	Ethylene glycol tetraacetic acid
EM	Electron microscopy
ER	Endoplasmic reticulum
FCS	Foetal calf serum
FITC	Fluorescein isothiocyanate
FKBP12	12-kDa FK506 binding protein
GST	Glutathione s transferase
HEK239T	Human embryonic kidney cells
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

IP3R	Inositol tri phosphate receptor
IP3	Inositol tri phosphate
IPTG	Isopropyl- $\beta$ -D-1-thiogalactopyranoside
IVCT	<i>In vitro</i> contracture test
kDa	Kilo Dalton
LB	lysogeny broth
MBP	Maltose binding protein
MH	Malignant hyperthermia
MHN	Malignant hyperthermia negative
MHS	Malignant hyperthermia susceptible
MS	Mass spectrometry
NTD	N-terminal domain
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
PDI	Protein disulphide isomerase
PVDF	Polyvinylidene fluoride
RIH	Ryanodine receptor, Inositol triphosphate receptor homology
RyR1	Ryanodine receptor protein
<i>RYR1</i>	Ryanodine receptor cDNA
SDS	Sodiumdodecylsulfate
SDS-PAGE	Sodiumdodecylsulfate-polyacrylamide gel electrophoresis
SEM	Standard error of the mean
SERCA	Sarco- and- endoplasmic reticulum ATP-ase
SR	Sarcoplasmic reticulum
TAE	Tris acetate EDTA buffer
TBST	Tris buffered saline Tween 20
TE	TE
TEMED	Tetramethylethylenediamine
Tris	Trisaminomethane
TRITC	Tetramethyl rhodamine isothiocyanate
T-tubule	Transverse tubule

# Table of contents

Acknowledgements .....	i
Abstract .....	ii
Abbreviations.....	ix
List of figures .....	xiv
List of tables .....	xvii
Chapter 1 Introduction .....	1
1.1 Malignant hyperthermia.....	1
1.2 Skeletal muscle .....	2
1.3 The ryanodine receptor .....	4
1.4 Variant mapping .....	5
1.5 Other RyR1 associated diseases.....	6
1.6 Regulation of RyR1 .....	7
1.6.1 Protein-protein interactions .....	7
1.6.2 Ligand interactions.....	10
1.7 Post translational modification of RyR1 .....	12
1.8 Pharmacology .....	13
1.9 Functional characterisation of MH-linked RyR1 variants .....	14
1.9.1 The <i>in vitro</i> contracture test .....	14
1.9.2 Myotubes .....	14
1.9.2 Lymphocytes.....	15
1.9.3 Human embryonic kidney cells .....	15
1.9.4 COS-7 .....	16
1.9.5 Dyspedic myotubes .....	16
1.9.6 Knock-in mice .....	17
1.9.7 Electrophysiology.....	17
1.10 Previously determined ryanodine receptor structures.....	18
1.11 Motivation for research described in this thesis .....	21
1.12 Hypothesis of study.....	22
1.13 Aims of study.....	22
Chapter 2 Materials and methods .....	24

2.1 Materials.....	24
2.2 Methods .....	25
2.2.1 Construction of <i>RYS1</i> variants and bacterial expression vectors.....	25
2.2.1.1 Site directed mutagenesis .....	25
2.2.1.2 Polymerase chain reaction (PCR) .....	25
2.2.1.3 PCR product purification.....	26
2.2.1.4 DNA sequencing.....	26
2.2.1.5 Restriction endonuclease digest.....	26
2.2.1.6 Antarctic phosphatase treatment of digested vectors.....	27
2.2.1.7 Digestion product purification .....	27
2.2.1.8 Ligation .....	27
2.2.1.9 Competent <i>E. coli</i> cells .....	27
2.2.1.10 Transformation of competent <i>E. coli</i> strains .....	28
2.2.1.11 Alkaline lysis plasmid isolation .....	28
2.2.1.12 Isolation of plasmid DNA: small scale .....	29
2.2.1.13 Isolation of plasmid DNA: medium scale .....	29
2.2.2 HEK293T cells .....	29
2.2.2.1 Cryo storage of HEK293T cells .....	29
2.2.2.2 Reanimation of HEK293T cells.....	29
2.2.2.3 Passaging of HEK293T cells .....	30
2.2.2.4 Coating of tissue culture plastic.....	30
2.2.2.5 Cell culture and transfection .....	30
2.2.2.6 SDS-PAGE .....	31
2.2.2.7 Immunoblotting .....	32
2.2.2.8 Immunofluorescence .....	33
2.2.2.9 Measurement of Ca <sup>2+</sup> release .....	34
2.2.2.10 Statistical analysis .....	34
2.2.3 Protein expression and purification from <i>E. coli</i> .....	35
2.2.3.1 Protein expression in <i>E. coli</i> .....	35
2.2.3.2 Protein extraction from BL21(DE3).....	35
2.2.3.3 <i>In vitro</i> refolding .....	35
2.2.3.4 Batch purification of protein expressed from the pGEX6p3 vector using glutathione sepharose 4B.....	36
2.2.3.5 Precision protease digestion .....	37

2.2.3.6 Batch purification of protein expressed from the pMALp2g vector using an amylose conjugated magnetic resin .....	37
2.2.3.7 Genenase digestion of protein expressed from the pMALp2g vector after elution from the amylose resin .....	38
2.2.3.8 Genenase digestion of protein expressed from the pMALp2g vector bound to the amylose resin .....	38
2.2.3.9 Mass spectrometry .....	39
Chapter 3 Functional characterisation of the RyR1 MH-linked variants p.T214M and p.ΔE2348.....	40
3.1 Introduction .....	40
3.2 Preparation of <i>RYR1</i> variant cDNA.....	41
3.2.1 Site directed mutagenesis .....	41
3.2.2 Confirming the identity of pBSXK 641C>T vector.....	44
3.2.3 Confirming the identity of pcNK 641C<T .....	45
3.2.4 Confirming the identity of the pc <i>RYR1</i> 641C<T, pc <i>RYR1</i> 641C<T/7042_7044delCAG and pc <i>RYR1</i> 7042_7044delCAG .....	46
3.3 Confirming the expression of RyR1 variants in HEK293T cells .....	46
3.4 Confirmation of RyR1 location within HEK293T cells .....	48
3.5 Analysis of RyR1 variant activity in HEK293T cells .....	50
3.5.1 Functional characterisation of RyR1 variants using 4- <i>CmC</i> .....	51
3.5.2 Optimisation of the caffeine induced Ca <sup>2+</sup> release.....	52
3.5.3 Functional characterisation RyR1 variants using caffeine .....	56
3.6 Measurement of resting cytosolic calcium levels .....	57
3.7 Discussion .....	59
3.8 Conclusion .....	62
Chapter 4 Overexpression and purification of the RyR1 N-terminal domain.....	63
4.1 Introduction .....	63
4.2 Results .....	67
4.2.1 Bioinformatics .....	67
4.2.2 Cloning strategy .....	71
4.2.3 Initial expression tests .....	73
4.2.4 Optimisation of expression .....	74
4.2.5 Codon optimisation of <i>RYR1</i> nucleotides 1-1674 .....	78

4.2.6 Characterisation of the RyR1 N-terminal domain expressed from the pGEX6p3 vector .....	79
4.2.7 Batch purification of the GST-tagged RyR1 N-terminal domain using glutathione sepharose 4B .....	80
4.2.8 PreScission protease digestion of the GST-tagged N-terminal domain ...	81
4.2.9 Confirmation of solubility of the cleaved N-terminal domain.....	85
4.2.10 Confirming the identity of the cleaved RyR1 N-terminal domain using mass spectrometry.....	86
4.2.11 Characterisation of the RyR1 N-terminal domain expressed from the pMALp2g vector.....	88
4.2.12 Batch purification of the pMALp2g expressed RyR1 N-terminal domain.	89
4.2.13 Genenase digestion of the MBP-tagged N-terminal domain .....	90
4.2.14 Confirming the identity of the RyR1 N-terminal domain.....	91
4.3 Chapter summary.....	92
Chapter 5 Over expression and purification of the RyR1 helical domain .....	94
5.1 Introduction .....	94
5.2 Results .....	97
5.2.1 Bioinformatic analysis .....	97
5.2.2 Cloning strategy .....	102
5.2.3 Initial expression .....	104
5.2.4 Optimisation of expression .....	105
5.2.5 <i>In vitro</i> re folding .....	107
5.2.6 Bioinformatic analysis .....	109
5.2.7 Cloning strategy .....	111
5.2.8 Optimisation of the expression of the proposed helical domain .....	111
5.2.9 Purification of the RyR1 helical domain using an amylose conjugated magnetic resin .....	114
5.2.10 Genenase digestion of the MBP-tagged RyR1 helical domain.....	115
5.2.11 Mass spectrometry to confirm the identity of the cleaved helical domain .....	118
5.3 Chapter summary.....	118
Chapter 6 Final summary and future directions .....	119
6.1 Functional characterisation of the RyR1 variants p.T214M and p.ΔE2348....	119

6.2 Over Expression and purification of the N-terminal and helical domains of RyR1 .....	119
6.3 Future directions .....	120
6.3.1 Functional characterisation of the RyR1 variants p.T214M and p.ΔE2348 .....	120
6.3.2 Structural characterisation of the RyR1 N-terminal domain and helical domain .....	123
6.3.3 Functional characterisation of the RyR1 N-terminal domain .....	125
6.5 Final summary.....	126
Reference list .....	128
Appendices.....	136

## List of figures

Figure 1.1 General architecture of a skeletal muscle fiber .....	2
Figure 1.2 Schematic representation of the factors controlling calcium homeostasis in skeletal muscle cells .....	3
Figure 1.3 Cryo-electron microscopy structure of RyR1 in the closed state, imaged at 6.1 Å resolution .....	5
Figure 1.4 Schematic representation of protein interactions with RyR1.....	9
Figure 1.5 Interaction between RyR1 DHPR $\alpha_{1s}$ loop II-III .....	10
Figure 1.6 Domain distribution of RyR1. A) Schematic representation of the proposed domain distribution of RyR1 .....	18
Figure 1.7 Location of the N-terminal domain with respect to the RyR1 tetramer.....	20
Figure 3.1 Sanger sequencing confirming the introduction of c.641C>T into the pBSXC+ vector.....	42
Figure 3.2 Representation of the cloning strategy used to construct the pcRYR1 c.641C>T and pcRYR1 c.641C>T/7042_7044delCAG vectors .....	43
Figure 3.3 Restriction endonuclease digestion to confirm the identity of the pBSXK 641C>T vector.....	44
Figure 3.4 Restriction endonuclease digestion to confirm the identity of the pcNK c.641C>T vector .....	45
Figure 3.5 Restriction endonuclease digestion to confirming the identity of pcRYR1 vectors.....	46
Figure 3.6 Immunoblot confirming the expression of RyR1 variants in HEK293T cells. ....	47
Figure 3.7 Immunofluorescent staining of transiently transfected HEK293T cells with RyR1 cDNA.....	50
Figure 3.8 $\text{Ca}^{2+}$ -release illustrated in 4-CmC concentration-response curves for transiently transfected HEK293T cells .....	51
Figure 3.9 $\text{Ca}^{2+}$ -release illustrated in caffeine concentration-response curves for transiently transfected HEK293T cells .....	53
Figure 3.10 $\text{Ca}^{2+}$ -release illustrated in caffeine concentration-response curves for transiently transfected HEK293T cells .....	55

Figure 3.11 Ca <sup>2+</sup> -release illustrated in caffeine concentration-response curves for transiently transfected HEK293T cells .....	56
Figure 4.1 A representation of the crystal structure of the N-terminal domain of the rabbit RyR1 .....	63
Figure 4.2 Location of the N-terminal domain with respect to the RyR1 tetramer.....	64
Figure 4.3 Sequence alignment of the RIH domain from human RyR1 and human IP3R .....	65
Figure 4.4 Super position of the rabbit RyR1 N-terminal domain ABC structure with the IP3R BC structure in the IP3 bound state .....	66
Figure 4.5 Sequence alignment of the N-terminal domain of ryanodine receptor isoforms from a range of organisms .....	69
Figure 4.6 Sequence alignment of human and rabbit RyR1 N-terminal domain and secondary structure prediction of the human RyR1 .....	70
Figure 4.7 PCR amplification of the <i>RYR1</i> cDNA nucleotides 1-1674 .....	72
Figure 4.8 An example the expression of the RyR1 N-terminal domain in BL21(DE3) cells .....	74
Figure 4.9 Rare codons within the <i>RYR1</i> nucleotides 1-1674 with respect the <i>E. coli</i> genome .....	77
Figure 4.10 Expression of the <i>RYR1</i> codon optimised cDNA from the pGEX6p3 vector.....	79
Figure 4.11 Batch purification of RyR N-terminal domain using glutathione sepharose 4B .....	80
Figure 4.12 PreScission protease digestion of the GST-tagged RyR1 N-terminal domain.....	82
Figure 4.13 Immunodetection confirming the identity of proteins following PreScission protease digestion .....	83
Figure 4.14 Confirming the specificity of interaction between cleaved RyR1 N-terminal domain and the glutathione sepharose 4B .....	85
Figure 4.15 Ultra centrifugation of the cleaved RyR1.....	86
Figure 4.16 MS/MS results for the gel purified RyR1 N-terminal domain.....	87
Figure 4.17 Expression of codon optimised RYR1 cDNA from the pMALp2g vector	88
Figure 4.18 Batch purification of MBP-tagged N-terminal domain .....	89
Figure 4.19 Genenase digestion of the MBP-tagged RyR1 N-terminal domain.....	91

Figure 4.20 Genenase digestion of the MBP-tagged N-terminal domain bound to the amylose resin .....	92
Figure 5.1 Location of the central region with respect to the RyR1 channel tetramer .....	94
Figure 5.2 Domain distribution of the RyR1 monomer .....	95
Figure 5.3 Sequence alignment of the RIH domain from RyR1 and IP3R .....	96
Figure 5.4 Sequence alignment of RyR1 and RyR2 HD1 regions from a range of organisms .....	98
Figure 5.5 Secondary structure prediction of the RyR1 amino acids 2269-2525 ....	100
Figure 5.6 Sequence alignment of the proposed ATP binding motif of RyR1, RyR2 and three examples of P-loop kinases .....	101
Figure 5.7 PCR amplification of <i>RYR1</i> nucleotides 6,807-7,575.....	103
Figure 5.8 the RyR1 helical domain expressed from the pProEXHTb vector .....	105
Figure 5.9 <i>In vitro</i> re folding of the RyR1 amino acids 2269-2525 expressed from the pProEXHTb vector .....	108
Figure 5.10 Secondary structure prediction of the human RyR1 amino acids 2091-2525 .....	110
Figure 5.11 Expression of the RyR1 helical domain from pMALp2g vector .....	112
Figure 5.12 MS/MS results for the gel purified MBP-tagged RyR1 helical domain .	113
Figure 5.13 Purification of the MBP-tagged RyR1 helical domain using an amylose conjugated resin .....	114
Figure 5.14 Genenase digestion of the MBP-tagged RyR1 helical domain .....	116
Figure 5.15 On resin genenase digestion of the MBP-tagged RyR1 helical domain .....	117
Figure 5.16 MS/MS results for the gel purified RyR1 helical domain .....	118

## List of tables

Table 1.1 List of components used for either 7 % or 12.5 % SDS-PAGE .....	32
Table 3.1 EC <sub>50</sub> for RyR1 variants following activation by 4-CmC. Results are represented as mean ± SEM.....	52
Table 3.2 EC <sub>50</sub> for RyR1 variants following activation by caffeine .....	57
Table 3.3 resting Ca <sup>2+</sup> of RyR1 variants in HEK293T cells .....	58
Table 4.1 The predicted physical properties of the RyR1 N-terminal domain in conjunction with the N-terminal tag expressed from a range of vectors.....	73
Table 4.2 Summary of the solubility of the amino acids 1-558 expressed from a range of expression vectors in BL21 (DE3).....	75
Table 4.3 Summary of the solubility of the amino acids 1-558 expressed from a range of expression vectors in Rosetta (DE3).....	76
Table 4.4. Expression summary of codon optimised <i>RYR1</i> N-terminal domain expressed from a range of vectors in BL21(DE3) cells. ....	78
Table 4.5 Proposed physical properties of the GST-tagged RyR1 N-terminal domain. ....	81
Table 4.6 Proposed physical properties of the MBP-tagged RyR1 N-terminal domain .....	90
Table 5.1 Predicted physical properties of the RyR1 amino acids 2269-2525 expressed from a range of expression vectors .....	104
Table 5.2 Summary of the solubility of RyR1 amino acids 2269-2525 expressed from a range of expression vectors in BL21 (DE3) cells .....	106
Table 5.3 Summary of the solubility of RyR1 amino acids 2269-2525 expressed from a range of expression vectors in Rosetta (DE3) cells. ....	106
Table 5.4 Summary of the solubility of RyR1 amino acids 2269-2525 expressed from a range vectors in BL21(DE3) Gro ES/EL.....	107
Table 5.5 Predicted physical properties of the RyR1 amino acids 2091-2525 expressed from the pProEXHTb and pMALp2g vectors .....	111
Table 5.6 Summary of the solubility of RyR1 amino acids 2091-2525 expressed from the pProEXHTb and pMALp2g vectors in BL21(DE3) cells. ....	112
Table 5.7 Predicted physical properties of the RyR1 helical domain following genenase digestion. ....	115